tbuckley/cabot-search huggingface dataset:
303P Biliary tract cancers (BTC): Descriptive and prognostic analyses from a large real-world dataset: The BITCOIN 2 study
Authors: M.D. Rizzato, V. Angerilli, A. De Rosa, D. Sacchi, G. Barsotti, V.M. Piva, M.C. De Grandis, C. Soldà, R. Intini, A.A. Prete, M. Sabbadin, R. Cerantola, K. Cerma, L. Procaccio, C. Ceccon, E. Perissinotto, E. Carcea, S. Lonardi, F. Bergamo, M. Fassan
Journal: Annals of Oncology (2024)
358P Clinical outcomes of patients with chemo-refractory pancreatic adenocarcinoma participating in phase I clinical trials
Authors: M. Sasaki, T. Satake, K. Watanabe, H. Imaoka, T. Shibuki, K. Inoue, T. Taira, G. Igarashi, S. Yamaguchi, S. Mitsunaga, M. Ikeda
Journal: Annals of Oncology (2024)
496TiP Randomised phase II study evaluating trifluridine/tipiracil (FTD/TPI) plus oxaliplatin ± nivolumab versus FOLFOX ± nivolumab in patients with HER2-negative locally advanced, recurrent or metastatic gastric, oesophageal or junctional adenocarcinoma (aGA/GEJA) (PRODIGE 73 - LOGICAN)
Authors: C. de la Fouchardiere, S. Chabaud, H. Perrier, H. Ammarguellat, V. Jestin, J. Olesinski, C. Toullec, T. Aparicio, M. Ben Abdelghani, O. Bouche, C. Coutzac, O. Dubreuil, L. Evesque, M. Muller, P-G. Poureau, E. Soularue, D. Tougeron, A. Zaanan, N. De Sousa Carvalho, D. Botsen
Journal: Annals of Oncology (2024)
386P Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts)
Authors: A. Lahusen, M.P. Lutz, M. Karthaus, M. Kirchner, P.F. Cheung, S. Wisser, N. Ansorge, G. Barmashenko, S. Hoefling, T. Leidig, M. Schulte, D.T. Waldschmidt, J. Budczies, J.T. Siveke, A. Tannapfel, A. Stenzinger, T.J. Ettrich, T. Eiseler, S. Raeth, T. Seufferlein
Journal: Annals of Oncology (2024)
LBA2 Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC)
Authors: F. Sclafani, G. Bregni, I. Assaf, F. Puleo, P. Vergauwe, H. Prenen, M. Diaz, Y. Gokburun, A. Veron Sanchez, G. Anthoine, L. Moretti, M. Gomez Galdon, G. Liberale, P. Martinive, K. Geboes, J. Carrasco, M. van den Eynde, J-L. van Laethem, M.E. Buyse, A. Hendlisz
Journal: Annals of Oncology (2024)
351P Correlation between overall survival and progression-free survival in advanced pancreatic cancer: Results of NAPOLEON-1 and 2 studies
Authors: T. Shirakawa, T. Araki, M. Shimokawa, M. Kawahira, T. Otsuka, T. Shibuki, J. Nakazawa, S. Arima, K. Miwa, F. Koga, Y. Ueda, Y. Kubotsu, H. Shimokawa, S. Takeshita, K. Nishikawa, A. Hosokawa, H. Oda, S. Arita, T. Mizuta, K. Mitsugi
Journal: Annals of Oncology (2024)
448P Disitamab vedotin (RC48) combined with programmed death-1 inhibitor for pre-treated HER2 expressed (IHC 2+/3+) advanced gastric cancer: A multi-center real-world study
Authors: X. Yan, Z. Xie, K. Ouyang, M. Lai, Y. Li, T. Huang, H. Liang, K. Huang, M. Qiu, L. Zhao
Journal: Annals of Oncology (2024)
458P Treatability with combination chemotherapy and eligibility for addition of new drugs in all gastroesophageal cancer patients referred for medical treatment 2016-2022 at a tertiary centre serving 540.000 inhabitants
Authors: P.J. Osterlund, M.T. Barlund, A. Osterlund, J. Kontiainen, T. Mikkola, S. Kukkurainen, K.I. Lehtomaki
Journal: Annals of Oncology (2024)
479P Survival outcomes of resected gastroesophageal cancer and impact of active surveillance: Experience from a tertiary centre
Authors: J. Chamorro-Perez, G. González Martín, E. Corral de la Fuente, V. Albarrán Fernández, D.I. Rosero Rodriguez, M.V.V. San Roman Gil, R. Ferreiro Monteagudo, I. Martínez Delfrade, B.I. Morón, B. de Frutos González, P. Reguera Puertas, J.J. Serrano Domingo, M.A. Vaz Salgado, M.L. Villamayor Delgado, C. Guillen Ponce, V. Lopez Gomez, M. Rodriguez, A. Carrato Mena, P. Garrido Lopez, F. Longo Muñoz
Journal: Annals of Oncology (2024)
443P TRIfluridine vs FOLfiri in thIrd-Line Metastatic gastroesophageal adenocarcinoma (mGEA): The TRIFOLIUM study
Authors: E. Perissinotto, R. Cerantola, M.C. De Grandis, R. Intini, A. De Rosa, G. Di Paolo, A.A. Prete, G. Barsotti, G. Ricagno, S. Sperotto, L. Procaccio, V.M. Piva, A. Roma, M.D. Rizzato, S. Ahcene Djaballah, F. Bof, C. Gaiani, F. Bergamo, S. Lonardi, S. Murgioni
Journal: Annals of Oncology (2024)
424P Pembrolizumab and olaparib in advanced HER2-negative esophagogastric adenocarcinoma: First results of the phase II AIO IKF-038/POLESTAR trial
Authors: G.M. Haag, T.O. Goetze, P.C. Thuss-Patience, J. Riera Knorrenschild, S. Lorenzen, N. Homann, T.J. Ettrich, T. Walle, A. Stenzinger, A. Brobeil, M. Schaaf, C. Pauligk, S-E. Al-Batran, A. Stein
Journal: Annals of Oncology (2024)
438P Adjuvant nivolumab after neoadjuvant chemoradiotherapy and surgery for patients with esophageal or gastroesophageal junction cancer: A nationwide real-world matched comparison of overall survival
Authors: R.H.A. Verhoeven, S.C. Kuijper, M. Slingerland, B.P.L. Wijnhoven, M.I. van Berge Henegouwen, P.S.N. van Rossum, S. Derks, B. Mostert, N. Haj Mohammad, H.W.M. van Laarhoven
Journal: Annals of Oncology (2024)
459P Layer analysis based on RNA-seq data of TCGA reveals gastric cancer's molecular complexity
Authors: J.P. Perez Wert, S. Hernández-Fernández, A. Gámez, M. Arranz-Alvarez, I. Ghanem, R. López-Vacas, M. Diaz-Almirón, C. Mendez, J-A. Fresno-Vara, J. Feliu, A. Custodio, L. Trilla
Journal: Annals of Oncology (2024)
490P Activating EGFR/HER3-induced epithelial-mesenchymal transition by ESM1 promotes gastric cancer progression via modulating interplay between Akt and angiopoietin-2 signaling
Authors: Y-C. Yang, K-F. Pan, W-J. Lee, M-C. Tung, M-H. Chien
Journal: Annals of Oncology (2024)
464P Enhancing management of localized gastric cancer: The added value of prophylactic HIPEC and IORT to conventional surgery
Authors: M. Shouki Ahmad A Bazarbashi, H. Elwaheidi, A. Sheikh, A. Aljuhani, M. Aseafan, A. Aljubran, A.M. Alzahrani, M.S. Rauf, F.A. Almugbel, A. Alqahtani, T. Elhassan
Journal: Annals of Oncology (2024)
423P Multicentre, multi-cohort, single-arm phase II trial of tremelimumab and durvalumab as neoadjuvant or definitive treatment of patients (pts) with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): The INFINITY study
Authors: A. Raimondi, S. Lonardi, S. Murgioni, G. Cardellino, A. Passardi, G. Demanzoni, A. Strippoli, F. Palermo, M. Prisciandaro, F. Bergamo, S.K. Garattini, G.L. Frassineti, M. Bencivenga, G. Randon, A.G. Leone, F. Nappo, V. Mazzaferro, C.F. Sposito, F. Morano, F. Pietrantonio
Journal: Annals of Oncology (2024)
428P Total neoadjuvant FOLFIRINOX in patients with resectable locally advanced gastric and gastroesophageal junction cancer: Updated survival results
Authors: M. Sedova, M. Batov, A. Kolomeytseva, V. Khomyakov, N. Volchenko, A.A. Fedenko, A. Kaprin
Journal: Annals of Oncology (2024)
425P Updated results of induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally advanced esophageal and gastroesophageal junction cancer: A phase II study
Authors: G. Gim, J. Zhao, N.J. Badri, M. McGreevy, M.S. Noel, A.M. Baran, W. Wang, E.E. Ramsdale, J. Zittel, D.L. Mulkerin, H. Qiu, A.W. Katz, A.R. Huber, C.E. Jones, C.G. Peyre, M.J. Lada, P.L. Feingold, A.F. Hezel, M.A. Tejani, R.F. Dunne
Journal: Annals of Oncology (2024)
441P Fat-free mass index combined with neutrophil-lymphocyte ratio as a promising marker for predicting oncological outcomes in gastric cancer: A large-sample study
Authors: Z. Yao, G-T. Lin, Q. Zhong, J. Lu, Z-Y. Liu, D. Wu, J-Y. Chen, Y-M. Jiang, C-H. Zheng, P. Li, J-W. Xie, C. Huang, S. Zhixin
Journal: Annals of Oncology (2024)
472P Homologous-recombination deficiency (HRD) in gastroesophageal adenocarcinoma (GEA): Clinical and molecular features
Authors: D. Acosta Eyzaguirre, G. Castillo, S. Aguilar Izquierdo, M. Cruellas Lapena, A. Herencia Ropero, S. Landolfi, H. Palma, T. Tian, A. Vivancos, V. Serra Elizalde, T. Macarulla Mercade
Journal: Annals of Oncology (2024)
487P HER2DX ERBB2 mRNA assay following trastuzumab-based chemotherapy in HER2-positive (HER2+) advanced gastric cancer (AGC)
Authors: T. Sauri Nadal, D.S. Pesantez Coronel, F. Braso Maristany, A. Indacochea, M. Cuatrecasas, E. Sanfeliu Torres, S. Lopezprades, L. Candia, G. Fernandez-Esparrach, I. Mendez, M. Nogue Aliguer, D. Momblan, L. Angelats, T. Pascual, A. Prat
Journal: Annals of Oncology (2024)
444P Clinicopathological characteristics and prognosis of HER2-low advanced/metastatic gastric cancer
Authors: W.W.L. Chan, H. Hou, R. Liu, K.O. Lam, P.Y.R. Tse, E. Cheung, I-H. Wong, S. Law, D.L.W. Kwong
Journal: Annals of Oncology (2024)
453P Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset gastric cancer: A retrospective cohort study on 18877 patients managed from 2000 to 2022 in a Chinese cancer center
Authors: Y. Liu, X. Zhang, H. Sun, X. Wang, X. Wang, J. Zhang, M. Xu, W. Sheng
Journal: Annals of Oncology (2024)
450P Neoadjuvant chemo-immunotherapy in mismatch repair deficient (dMMR)/microsatellite instability (MSI) gastric carcinoma (GC): A multicenter retrospective study
Authors: H. Sun, V. Moiseyenko, V. Chubenko, I. Gerk, A. Navmatulya, K.V. Shelekhova, N.M. Volkov, E. Zykov, V. Chernobrivceva, S. Nered, N. Besova, E. Obarevich, D. Gavrilova, P. Kononets, I. Stilidi, N. Belyak, R.V. Orlova, E. Topuzov, Y. Pelipas, A. Tryakin
Journal: Annals of Oncology (2024)
437P Early gastric cancer detection with AI-enabled routine blood test: A territory-wide clinical big-data study
Authors: M. Seo, K.M. Cheung, S.J.L. Lam, W. Sung, P.Y.M. Woo, J.C-H. Chow, A.S.M. Yip, S.K.K. Ng, M. Lee, D.M.Y. Kan, S. Kao, H.H.Y. Yiu, D.C.C. Lam
Journal: Annals of Oncology (2024)
463P A real-world study to evaluate biomarker testing and treatment management in patients with locally advanced unresectable or metastatic G/GEJ adenocarcinoma in France, Germany, Italy, Spain, UK and Canada: Adelphi Real World G/GEJ cancer disease specific programme
Authors: F. Lordick, E. Roncancio-Diaz, K. Lewis, A. Lambert, G. Thomason, E. Brown, A. Van Oosten, G. Gourgioti, C. Streutker, F. Rivera Herrero, A. Chilelli
Journal: Annals of Oncology (2024)
482P Blood-based oxidative phosphorylation-related gene signature and their SNPs as novel prognostic biomarkers for gastric cancer patients treated with nivolumab
Authors: C. Inagaki, R. Matoba, H. Lijuma, J. Hihara, H. Yasui, N. Takegawa, T. Suzuki, A. Makiyama, H. Yabusaki, J. Matsuyama, M. Takahashi, Y. Kito, Y. Akamaru, A. Ishiguro, R. Kawabata, Y. Sakamoto, E. Inoue, W. Ichikawa, M. Fujii, Y. Sunakawa
Journal: Annals of Oncology (2024)
471P Risk factors associated with recurrence and survival in patients with locally advanced gastric cancer: Experience in a single center
Authors: S.M. Miyagui Adame, M.D.C. Diaz Romero, J. Cervantes Bojalil, V. Salais Michaus, G. Calderillo Ruiz, M. Herrera, E. Ruiz, S. Zilli Hernández, A.W. Saenz Mamani, J. Melchor-Ruan
Journal: Annals of Oncology (2024)
421P Maintenance therapy with regorafenib (REGO) versus placebo after first-line (1L) platinum and fluoropyrimidines-based chemotherapy in HER2-negative advanced gastric (GC)/gastroesophageal junction (GEJ) cancer: Results of phase II randomized a-MANTRA study (GOIRC-05-2016)
Authors: A. Damato, D. Bilancia, F. Iachetta, A. Strippoli, F. Filiali, R. Casaretti, I. Bernardini, G. Bellotti, G.L. Frassineti, F. Di Fabio, M. Aieta, M. Ghidini, C. Trentin, G. Cardellino, E. Gervasi, A. Romagnani, S. Cinieri, N. Normanno, L. Boni, C. Pinto
Journal: Annals of Oncology (2024)
430P Is Ga68-FAPI PET-CT a new imaging standard in poorly cohesive carcinoma stomach? An initial experience in comparison to FDG PET-CT
Authors: M. Gupta, S. Singh, V. Talwar, S. Goyal, U. Batra, S. Goel, G. Gupta, V. Goel, S.S. Mathighatta Shivarudraiah, P.S. Choudhury
Journal: Annals of Oncology (2024)
474P A clinical model based on skeletal muscle radiation attenuation associated with efficacy of gastric cancer treatment with chemotherapy plus PD-1 antibodies: A single-center retrospective study
Authors: C. Zhou, Y. Sun, D.P.J. van Dijk, W. Xi, J. Jiang, L. Guo, J. Wu, F. Qi, X. Zhang, J. Ji, Q. Cai, Z. Zhu, S.S.M. Rensen, S.W.M. Olde Damink, J. Zhang
Journal: Annals of Oncology (2024)
434P First-line oxaliplatin-based chemoimmunotherapy for advanced HER2/neu-negative gastric and gastroesophageal junction cancer: A systematic review and network meta-analysis
Authors: A. Al Zahrani, R. Alsuwailem, F. Alghamdi, A. Alfahadi, T. Elhassan, S. Yezli
Journal: Annals of Oncology (2024)
415P Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable locally advanced esophageal squamous cell carcinoma
Authors: Y. Yoshinami, S. Yamamoto, K. Shiraishi, M. Itoyama, H. Imazeki, K. Yokoyama, Y. Honma, D. Kurita, K. Ishiyama, J. Oguma, H. Daiko, K. Kato
Journal: Annals of Oncology (2024)
492TiP HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first-line treatment for HER2-positive esophageal squamous cell carcinoma patients
Authors: K. Egebjerg, L. Baeksgaard, R. Garbyal, P. Pfeiffer, T. Caterino, J.K. Bjerregaard, M.N. Yilmaz, A. Wanders, L.B.J. Thorsen, S. Hamilton Dutoit, L. Ahlborn, N. Pallisgaard, P.M. Mau-Sorensen
Journal: Annals of Oncology (2024)
422P HLX22 plus HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric/gastroesophageal junction cancer: Updated results from a randomized, double-blind phase II study
Authors: J. li, Y. Gao, N. Li, M. Qiu, Y. Zhang, M. Yang, L. Lu, W. Li, Y. Ma, X. Hou, G. Sun, M. Cai, J. Wang, J. Lu, D. Zhong, F. Yang, H. Yu, J. Li, Q. Wang, J. Zhu
Journal: Annals of Oncology (2024)
456P Correlation between pathological complete response (pCR) and survival outcomes in patients with resectable esophageal (EC) or gastroesophageal junction cancer (GEJC): A large, real-world, single-center cohort analysis
Authors: M. Airoldi, A. Pansa, L. Giordano, M. Bartolini, V. Daprà, R. Fazio, M.G. Prete, G. Mondello, M.C. Tronconi, S. Marano, S. Basato, R. Alfieri, A. Capogreco, D. Franceschini, P. Spaggiari, M. Scorsetti, A. Santoro, C. Castoro, A. Puccini
Journal: Annals of Oncology (2024)
477P Association of gastric background mucosa status with the efficacy of immune checkpoint inhibitors in patients with unresectable advanced gastric cancer
Authors: Y. Kamijo, Y. Nagata, H. Suzuki, H. Kunimoto, A. Seki, Y. Sekino, M. Sakon, H. Ushimaru, E. Hara
Journal: Annals of Oncology (2024)
420P Q-TWiST analysis of nivolumab + chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC) in patients with PD-L1 CPS≥1 and CPS≥5: 4-year follow-up from CheckMate 649 (CM 649)
Authors: D. Lin, W. Quan, M. Garretson, V.V. Chirikov, C. Chen, P. Singh, C. Davis, R. Sugarman
Journal: Annals of Oncology (2024)
469P 16-year outcomes of radically treated localized gastric cancer (GC) patients (pt): Real-world data (RWD) of a Spanish institution
Authors: I. Macias Declara, S. Soriano, P. Ribera Fernandez, R. Querol Ninerola, S. Navarro, F. Rivera Herrero, C. Hierro Carbo, A.L. Luna, N. Perez Romero, T. Sauri Nadal, M.A. Segui Palmer, C. Pericay Pijaume
Journal: Annals of Oncology (2024)
451P Assessment of PD-L1 on matched surgical specimen and biopsy in resectable esophagogastric cancer (EGC): The APEROL study
Authors: F. Nappo, G. Ricagno, C. Ceccon, M. Sabbadin, S. Ahcene Djaballah, A. Roma, G. Di Paolo, E. Perissinotto, A. De Rosa, R. Cerantola, V. Angerilli, I. Montagner, E. Carcea, P. Pilati, M. Valmasoni, A. Scapinello, F. Bergamo, S. Lonardi, M. Fassan, S. Murgioni
Journal: Annals of Oncology (2024)
432P Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase I/II trial (SYLT-023)
Authors: R. Lin, Z. Ye, C. Zhuo, S. Wei, Z. Li, S. Zhao, L. Su
Journal: Annals of Oncology (2024)
419P Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4-year (y) follow-up (FU) of CheckMate 649
Authors: L.S. Wyrwicz, K. Shitara, M. Moehler, J.A. Ajani, L. Shen, M. Garrido, C.E. Gallardo Araneda, K. Yamaguchi, J. Cleary, E. Elimova, R. Brugés Maya, M.V. Karamouzis, T. Skoczylas, A.C. Bragagnoli, T. Liu, M. Tehfe, K. Feeney, R. Wang, J. Zhang, Y.Y. Janjigian
Journal: Annals of Oncology (2024)
465P Timing of first-line palliative systemic therapy in metastatic Esophagogastric cancer (mEGC): A European Delphi study
Authors: D. Kamp, A.M. May, A. Adenis, A. Capela Marques, S. Derks, F. Defelice, N. Fokter Dovnik, C. Hierro Carbo, A. Ilhan-Mutlu, F. Lordick, R. Obermannova, A. Petrillo, A. Puccini, A.C. Raimundo, G. Roviello, A.R. Siebenhüner, M. Slingerland, E. Smyth, H.W.M. van Laarhoven, N. Haj Mohammad
Journal: Annals of Oncology (2024)
493TiP A phase II study of mFOLFOX6 plus nivolumab as initial therapy for patients with advanced esophageal squamous-cell cancer: FLONTALE trial
Authors: Y. Kubota, S. Ueyama, Y. Yamamoto, Y. Amanuma, M. Furuta, S. Sato, T. Tsushima, T. Moriwaki, K. Tanabe, Y. Sunakawa
Journal: Annals of Oncology (2024)
442P AI routine blood signature as a tumour marker to predict post-treatment outcomes in gastric cancer
Authors: K.M. Cheung, M. Seo, S.J.L. Lam, W. Sung, P.Y.M. Woo, J.C-H. Chow, A.S.M. Yip, H. Liu, S.K.K. Ng, M. Lee, D.M.Y. Kan, S. Kao, H.H.Y. Yiu, D.C.C. Lam
Journal: Annals of Oncology (2024)
462P Noninterventional cohort study of biomarker testing and treatment patterns in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer
Authors: S.J. Klempner, R. Fuldeore, A. Brackey, C. Sangli, S. Nishtala, D. Nimke, S. Braun, R. Mehta
Journal: Annals of Oncology (2024)
486P Genomic profile differences between primary and recurrent tumors in curatively resected gastric cancer: The Liquid-GEAR study
Authors: H. Takeda, R. Kawabata, A. Ishiguro, S. Nishina, M. Takahashi, S. Suzuki, T. Suzuki, J. Matsuyama, Y. Otsuki, Y. Akamaru, N. Takegawa, T. Nomura, Y. Kito, H. Yabusaki, Y. Negoro, A. Makiyama, M. Nakamura, M. Takahashi, Y. Sunakawa
Journal: Annals of Oncology (2024)
460P Real-world study of ramucirumab and paclitaxel as ≥2nd-line therapy in patients with HER2-positive gastroesophageal cancer
Authors: Y. Bach, D. Sharma, E.X. Chen, L. Ma, R.W-J. Jang, X. Wang, R.A. Mclaughlin, H. Aoyama, Y. Yang, S. Akhtar, T. Megid, C. Barron, A. Farooq, A. St Bernard, E. Elimova
Journal: Annals of Oncology (2024)
485P Heterogeneity and dynamic changes of PD-L1 expression and CPS score in patients with gastroesophageal malignancies
Authors: M.E. Salem, S. Wu, J. Xiu, S.K. Deshmukh, A. Puccini, D. Foureau, J.J. Hwang, J. Marshall, R.M. Goldberg, H.J. Lenz, T. Sanlung, R.T. Shroff, W. Zhang, M. Oberley, B. Weinberg, S. Goel
Journal: Annals of Oncology (2024)
489P SDF-1alpha, SCF, and eotaxin are prognostic serum biomarkers in gastric cancer
Authors: J. Brodkin, T. Kaprio, H. Mustonen, A. Leppä, A. Kokkola, M. Salmi, S. Jalkanen, C. Haglund, C. Böckelman
Journal: Annals of Oncology (2024)
468P Association of prior and concurrent malignancies with overall survival in a large European single-center gastroesophageal cancer cohort
Authors: H.C. Puhr, L. Berchtold, L. Zingerle, M. Korpan, J.M. Berger, G. Jomrich, R. Asari, S. Schoppmann, G. Prager, E.S. Bergen, A.S. Berghoff, M. Preusser, A. Ilhan-Mutlu
Journal: Annals of Oncology (2024)
446P A prospective study for real-world data (RWD) of ramucirumab plus paclitaxel in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KCSG ST21-06)
Authors: D.Y. Zang, C.H. Maeng, J.Y. Kim, M.H. Ryu, K-W. Lee, M. Jung, H.S. Han, B. Kim, D-Y. Oh, J.G. Kim, I-H. Kim, S.J. Sym, J-J. Kim, W. Choi, S.H. Shin, S.Y. Kang, E-K. Song, H-S. Im, J.H. Cho, S.T. Kim
Journal: Annals of Oncology (2024)
495TiP CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)
Authors: K. Shitara, Y.Y. Janjigian, E. Elimova, J. Zhang, M-H. Chen, E. Smyth, J. Lee, R. Miao, S. Liu, M. Holmblad, R-H. Xu
Journal: Annals of Oncology (2024)
483P Germinal centre microarchitecture in tumour-negative lymph nodes after different neoadjuvant chemotherapy regimens in patients with oesophagogastric cancer: Results from the UK MRC OE05 trial
Authors: M. Kloft, E. Budginaite, D.R. Magee, M.G. Nankivell, R.E. Langley, J. Stokes, D. Cairns, G. Verghese, M. Li, A. Grigoriadis, D. Cunningham, H.I. Grabsch
Journal: Annals of Oncology (2024)
399P A Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) analysis comparing nivolumab plus chemotherapy (N+CT) or nivolumab plus ipilimumab (N+I) vs CT in patients (pts) with tumor cell PD-L1 ≥ 1% advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648
Authors: I. Chau, J.A. Bridgewater, L.S. Wyrwicz, M. Greenwood, S.I. Blum, A. Moreno-Koehler, E. Martin, F. Taylor, C. Davis, P. Singh
Journal: Annals of Oncology (2024)
395MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306
Authors: E. Raymond, J. Xu, K. Kato, R. Hubner, Y. Shu, S.R. Park, T. Kojima, L.S. Wyrwicz, D. Tougeron, K. Geboes, E. Van Cutsem, R.A. Pazo Cid, A. Zaanan, S-A. McLachlan, H. Wu, J. Shi, L. Li, S. Yan, H. Yoon
Journal: Annals of Oncology (2024)
279MO Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in biliary tract cancer (BTC)
Authors: D-Y. Oh, A.R. He, S. Qin, L-T. Chen, T. Okusaka, A. Vogel, J.W. Kim, T. Suksombooncharoen, M.A. Lee, M. Kitano, H.A. Burris, M. Bouattour, S. Tanasanvimon, R.E. Zaucha, A. Avallone, J.E. Cundom, A. Kuzko, J. Wang, I. Xynos, J.W. Valle
Journal: Annals of Oncology (2024)
413P Following planned pre-operative (pre-op) chemo-radiotherapy (CRT) for squamous cell cancer (SCC) of the esophagus (eso), why do some patients not undergo surgery (sx)? A service evaluation from a tertiary care hospital in a Low-Middle Income Country (LMIC)
Authors: S. Kumar, K. Mangla, K. Parikh, S. Misra, R. Singh, N. Aggarwal, F. Ahmad, S. Pant, S. Singh, S. Sk
Journal: Annals of Oncology (2024)
396MO Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase I study
Authors: J.J. Liu, X. Yu, J. Zhang, J. Yang, J. Yue, Y. Sun, Y. Pan, M. Sun, Y. Qin, L. Shen, R. Song, J. Ruan, A. Zhou, Y. Mou, Z. Liu, Z. Liu, M. Morris, M. Aghmesheh, A. Tazbirkova, H. Zhou
Journal: Annals of Oncology (2024)
214P A multicenter retrospective study of ramucirumab-containing chemotherapy for gastrointestinal neuroendocrine carcinoma after platinum-based chemotherapy (WJOG13420G: RAM-NEC)
Authors: Y. Matsubara, T. Masuishi, W. Hosoda, M. Saori, H. Hirano, M. Furuta, K. Kawasaki, T. Shimura, K. Murayama, K. Minashi, M. Komoda, T. Otsuka, Y. Shinohara, S. Nishina, N. Musha, K. Kato, I. Oze, K. Muro
Journal: Annals of Oncology (2024)
300P Prognostic and predictive role of FGFR2 and IDH1 targetable alterations in advanced biliary tract cancer (aBTC): Data from the Italian ANITA dataset
Authors: V. Genovesi, M. Rimini, T. Pressiani, C. Soldà, F. Nichetti, L. Salvatore, L. Antonuzzo, L. Silvestro, A. Diana, F. Leone, S. Foti, R. Balsano, V.M. Piva, C.C. Pircher, S. Camera, G. Masi, L. Rimassa, M.C. De Grandis, A. Casadei Gardini, L. Fornaro
Journal: Annals of Oncology (2024)